Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Abeona Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ABEO
Nasdaq
8731
https://abeonatherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Abeona Therapeutics Inc
Abeona Therapeutics Reports Third Quarter 2022 Financial Results
- Nov 14th, 2022 12:30 pm
Cantor Bullish On Abeona Saying Recent Trial Data 'Best Case Scenario'
- Nov 8th, 2022 7:28 pm
Abeona Therapeutics Touts Positive Data From Pivotal EB-101 Study In Blistering Skin Disorder
- Nov 3rd, 2022 4:44 pm
Abeona Therapeutics Announces $35 Million Private Placement Financing
- Nov 3rd, 2022 11:31 am
Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101
- Nov 3rd, 2022 11:30 am
Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
- Oct 19th, 2022 11:30 am
Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
- Oct 4th, 2022 11:30 am
Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit
- Sep 22nd, 2022 11:30 am
Abeona Therapeutics to Participate in the Cantor Fitzgerald Cell and Genetic Medicines Conference
- Sep 13th, 2022 11:30 am
10 Best Penny Stocks to Buy in September
- Sep 8th, 2022 12:48 pm
Abeona Therapeutics Reports Second Quarter 2022 Financial Results
- Aug 11th, 2022 11:30 am
Abeona Therapeutics Regains Compliance with Nasdaq Listing Requirements
- Jul 20th, 2022 11:30 am
F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm
- Jun 24th, 2022 2:08 pm
bluebird (BLUE) Up as FDA Nod Likely for Thalassemia Therapy
- Jun 8th, 2022 5:21 pm
AstraZeneca (AZN) Breast Cancer Drug Cuts Risk of Death to Half
- Jun 6th, 2022 6:04 pm
Abeona Therapeutics to Present at the Jefferies Healthcare Conference
- Jun 6th, 2022 11:30 am
BioMarin (BMRN) Delays FDA Re-Submission for Hemophilia Drug
- Jun 1st, 2022 6:25 pm
Amicus' (FOLD) Galafold Aids Growth, Overdependence a Woe
- May 31st, 2022 6:27 pm
Aerie (AERI) Starts Late-Stage Study to Treat Dry Eye Disease
- May 25th, 2022 6:29 pm
Athersys (ATHX) Down as Ischemic Stroke Study Fails to Meet Goal
- May 23rd, 2022 7:32 pm
Scroll